Phase 2Active, not recruiting
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
- Sponsor
- Criterium, Inc. (Industry)
- Enrolment
- 70 planned
- Conditions
- Breast Cancer
- Interventions
- Palbociclib; Fulvestrant; Adjuvant Therapy
- Ages
- children, adults, older adults
- Registry
- NCT04567420
Full record on ClinicalTrials.gov
From the registry
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Primary outcomes
- Surveillance/ctDNA screening Phase
- Therapeutic Phase
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered